VAXELIS

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, United Kingdom, United States

Active ingredients

The drug VAXELIS contains a combination of these active pharmaceutical ingredients (APIs):

1 Diphtheria toxoid UNII IRH51QN26H - CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Diphtheria toxoid

2 Tetanus toxoid UNII K3W1N8YP13 - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Tetanus toxoid

3 Pertussis, purified antigen UNII F4TN0IPY37 - BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED)

Read about Pertussis, purified antigen

4 Pertussis filamentous hemagglutinin UNII 8C367IY4EY - BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Pertussis filamentous hemagglutinin

5 Pertussis, purified antigen UNII 63GD90PP8X - BORDETELLA PERTUSSIS PERTACTIN ANTIGEN

Read about Pertussis, purified antigen

6 Pertussis, purified antigen UNII 1O0600285A - BORDETELLA PERTUSSIS FIMBRIAE 2/3 ANTIGEN

Read about Pertussis, purified antigen

7 Poliomyelitis, serotype 1 UNII 0LVY784C09 - POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 1

8 Poliomyelitis, serotype 2 UNII 23JE9KDF4R - POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 2

9 Poliomyelitis, serotype 3 UNII 459ROM8M9M - POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 3

10 Hepatitis B, purified antigen UNII XL4HLC6JH6 - HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN

Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer. Read about Hepatitis B, purified antigen

11 Haemophilus influenzae B UNII LUY6P8763W - HAEMOPHILUS INFLUENZAE TYPE B CAPSULAR POLYSACCHARIDE MENINGOCOCCAL OUTER MEMBRANE PROTEIN CONJUGATE ANTIGEN

Haemophilus influenza type B (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in young children. Vaccines are the only public health tool capable of preventing the majority of serious Hib disease. Read about Haemophilus influenzae B

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07CA09	Diphtheria-Haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B	J Antiinfectives for systemic use → J07 Vaccines → J07C Bacterial and viral vaccines, combined → J07CA Bacterial and viral vaccines, combined
Discover more medicines within J07CA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1711347, 1711358, 1711369, 1849552
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1151079004
Country: FR	Base de données publique des médicaments	Identifier(s): 69688620
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 393672
Country: IT	Agenzia del Farmaco	Identifier(s): 044721013, 044721025, 044721037, 044721049, 044721052, 044721064, 044721076, 044721088
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1079673, 1079674, 1079675, 1079676, 1079677, 1079678, 1079680, 1089619
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 196541
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100366850
Country: US	FDA, National Drug Code	Identifier(s): 63361-243